Watch Live

Tweet TWEET

Hospira Announces Executive Changes

                     Hospira Announces Executive Changes

PR Newswire

LAKE FOREST, Ill., March 1, 2013

LAKE FOREST, Ill., March 1, 2013 /PRNewswire/ --Hospira, Inc. (NYSE: HSP),
the world's leading provider of injectable drugs and infusion technologies,
today announced that Royce R. Bedward has been appointed corporate vice
president, general counsel and secretary, effective immediately. In his new
role, Mr. Bedward will oversee the company's legal department, including
litigation, benefits, labor and employment, intellectual property, governance,
securities and transactional matters. He will report to Brian Smith, who has
served as Hospira's senior vice president and general counsel since its
spin-off in 2004, and now assumes the newly created role of chief legal
officer, including responsibility for government affairs. Both Mr. Smith and
Mr. Bedward will serve as members of the company's senior leadership team, led
by F. Michael Ball, chief executive officer.

(Photo: http://photos.prnewswire.com/prnh/20130301/CG69263)

"Royce is an accomplished lawyer and integrity-driven business leader with
more than 10 years of experience in the healthcare field and a proven track
record of success at Hospira," said Mr. Ball. "We look forward to Royce's many
additional contributions, while thanking Brian for his continued service and
counsel. Working together, I'm confident that their strong leadership
abilities will help position Hospira for a stronger future of sustainable,
long-term growth and drive greater value for our stakeholders."

Mr. Bedward, 47, is one of the founding members of Hospira's legal leadership
team, joining the company at its inception as its vice president of
litigation, and assuming roles of increasing responsibility, most recently
holding the position of deputy general counsel and secretary. Prior to the
company's spin-off from Abbott Laboratories, Mr. Bedward served as Abbott's
senior counsel, litigation, where his practice included patent issues related
to the Hatch-Waxman Act, defense of investigations, major commercial disputes,
product liability matters and arbitrations.

Mr. Bedward began his career as an attorney for the law firm Jenner & Block,
where he was ultimately promoted to partner. At the firm, he handled a wide
array of complex litigation matters, including fraud and business torts,
intellectual property matters, product liability and insurance recovery
actions.

Born in Madison, Wis., Mr. Bedward earned his bachelor's degree in business
administration, magna cum laude, from Saint Norbert College. He holds a juris
doctorate degree, magna cum laude, from the University of Illinois College of
Law, where he also served as an editor on the Law Review.

In another organizational move, Hospira announced that Sumant Ramachandra,
M.D., Ph.D., is resigning from his position as senior vice president and chief
scientific officer, effective March 8. Dr. Ramachandra has served in this role
since 2008. The company has initiated a search for his successor and
instituted an interim reporting structure that will ensure seamless
advancement of the company's research and development priorities, including
its global expansion and biosimilars programs.

Said Mr. Ball, "On behalf of Hospira, I'd like to thank Sumant for his many
contributions and wish him the best in his future endeavors. During his
tenure, we have established one of the most robust biosimilars pipelines in
the industry, expanded an already market-leading generic injectables portfolio
and built a talented scientific, medical and regulatory organization to
execute our vision for future success."

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion
technologies. Through its broad, integrated portfolio, Hospira is uniquely
positioned to Advance Wellness™ by improving patient and caregiver safety
while reducing healthcare costs. The company is headquartered in Lake Forest,
Ill., and has approximately 16,000 employees. Learn more at www.hospira.com.



SOURCE Hospira, Inc.

Website: http://www.hospira.com
Contact: Media, Lauren Denz, +1-224-212-2656, or Financial Community, Karen
King, or Ruth Venning, both at +1-224- 212-2711
 
Press spacebar to pause and continue. Press esc to stop.